Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Tuberculosis

Free Subscription Articles published in Respir Med Retrieve available abstracts of 13 articles: HTML format Text format

Single Articles

June 2019
1. FURUUCHI K, Morimoto K, Yoshiyama T, Tanaka Y, et al
   Interrelational changes in the epidemiology and clinical features of nontuberculous mycobacterial pulmonary disease and tuberculosis in a referral hospital in Japan.
   Respir Med. 2019;152:74-80.
   PubMed     Text format     Abstract available
   
   
   February 2019
2. BAN GY, Jeong YJ, Lee SH, Shin SS, et al
   Efficacy and tolerability of desensitization in the treatment of delayed drug hypersensitivities to anti-tuberculosis medications.
   Respir Med. 2019;147:44-50.
   PubMed     Text format     Abstract available
   
   
   September 2018
3. AZNAR ML, Zubrinic M, Siemienowicz M, Hashimoto K, et al
   Adjuvant lung resection in the management of nontuberculous mycobacterial lung infection: A retrospective matched cohort study.
   Respir Med. 2018;142:1-6.
   PubMed     Text format     Abstract available
   
   
   June 2018
4. SUN F, Li L, Liao X, Yan X, et al
   Adjunctive use of prednisolone in the treatment of free-flowing tuberculous pleural effusion: A retrospective cohort study.
   Respir Med. 2018;139:86-90.
   PubMed     Text format     Abstract available
   
   
   February 2018
5. SIKJAER MG, Lokke A, Hilberg O
   The influence of psychiatric disorders on the course of lung cancer, chronic obstructive pulmonary disease and tuberculosis.
   Respir Med. 2018;135:35-41.
   PubMed     Text format     Abstract available
   
   
   January 2018
6. SILVA DR, Sotgiu G, D'Ambrosio L, Pereira GR, et al
   Diagnostic performances of the Xpert MTB/RIF in Brazil.
   Respir Med. 2018;134:12-15.
   PubMed     Text format     Abstract available
   
   
   December 2017
7. KIM S, Lee H, Park HY, Jeon K, et al
   Outcomes of pulmonary tuberculosis in patients with discordant phenotypic isoniazid resistance testing.
   Respir Med. 2017;133:6-11.
   PubMed     Text format     Abstract available
   
   
   November 2017
8. BOTHAMLEY GH, Lange C
   Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug/extensively-resistant tuberculosis (M/XDR-TB) in Europe: A tuberculosis network European Trialsgroup (TBNET) study.
   Respir Med. 2017;132:68-75.
   PubMed     Text format     Abstract available
   
   
   October 2017
9. PARK S, Jo KW, Lee SD, Kim WS, et al
   Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
   Respir Med. 2017;131:43-48.
   PubMed     Text format     Abstract available
   
   
   April 2017
10. JO KW, Yeo Y, Sung H, Kim MN, et al
    Corrigendum to "Analysis of discrepant results between the Genotype(R) MTBDRplus assay and an antimicrobial-susceptibility test for isoniazid-resistant tuberculosis'"[Respiratory Med. 122 (January 2017) 12-17].
    Respir Med. 2017;125:24.
    PubMed     Text format    
    
    
    January 2017
11. JO KW, Yeo Y, Sung H, Kim MN, et al
    Analysis of discrepant results between the Genotype(R) MTBDRplus assay and an antimicrobial drug susceptibility test for isoniazid-resistant tuberculosis.
    Respir Med. 2017;122:12-17.
    PubMed     Text format     Abstract available
    
    
    October 2016
12. CERVANTES J
    Tuberculosis. Digging deep in the soul of humanity.
    Respir Med. 2016;119:20-22.
    PubMed     Text format     Abstract available
    
    
    July 2016
13. DIMAKOU K, Triantafillidou C, Toumbis M, Tsikritsaki K, et al
    Non CF-bronchiectasis: Aetiologic approach, clinical, radiological, microbiological and functional profile in 277 patients.
    Respir Med. 2016;116:1-7.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: